Silence Therapeutics PLC (SLN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Silence Therapeutics PLC (SLN) has a cash flow conversion efficiency ratio of 0.039x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($1.49 Million) by net assets ($38.47 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Silence Therapeutics PLC (SLN) total market value for the company's overall valuation and market capitalisation.
Silence Therapeutics PLC - Cash Flow Conversion Efficiency Trend (1995–2025)
This chart illustrates how Silence Therapeutics PLC's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Silence Therapeutics PLC Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Silence Therapeutics PLC ranked by their cash flow conversion efficiency. Explore earnings quality score of Silence Therapeutics PLC to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Regional Container Lines Public Company Limited
BK:RCL-R
|
0.054x |
|
Doman Building Materials Group Ltd
TO:DBM
|
0.161x |
|
BOROSIL RENEWABLES LIMITED
NSE:BORORENEW
|
0.152x |
|
MiMedx Group Inc
NASDAQ:MDXG
|
0.123x |
|
Campus Activewear Limited
NSE:CAMPUS
|
-0.029x |
|
Yoantion Industrial Inc.Ltd.
SHE:301053
|
N/A |
|
Shenzhen Lifotronic Technology Co
SHG:688389
|
0.025x |
|
CEWE Stiftung & Co. KGaA
XETRA:CWC
|
-0.010x |
Annual Cash Flow Conversion Efficiency for Silence Therapeutics PLC (1995–2025)
The table below shows the annual cash flow conversion efficiency of Silence Therapeutics PLC from 1995 to 2025. View latest Silence Therapeutics PLC stock price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $62.30 Million | $-62.27 Million | -0.999x | -97.95% |
| 2024-12-31 | $107.05 Million | $-54.05 Million | -0.505x | +77.67% |
| 2023-12-31 | $17.40 Million | $-39.35 Million | -2.261x | +12.52% |
| 2022-12-31 | $22.07 Million | $-57.04 Million | -2.584x | -339.89% |
| 2021-12-31 | $8.53 Million | $9.19 Million | 1.077x | +190.57% |
| 2020-12-31 | $9.06 Million | $-10.78 Million | -1.190x | -1540.18% |
| 2019-12-31 | $20.91 Million | $1.73 Million | 0.083x | +117.28% |
| 2018-12-31 | $35.05 Million | $-16.76 Million | -0.478x | -160.74% |
| 2017-12-31 | $52.35 Million | $-9.60 Million | -0.183x | +1.30% |
| 2016-12-31 | $54.18 Million | $-10.07 Million | -0.186x | -35.99% |
| 2015-12-31 | $60.43 Million | $-8.26 Million | -0.137x | +59.91% |
| 2014-12-31 | $27.76 Million | $-9.46 Million | -0.341x | -39.08% |
| 2013-12-31 | $27.58 Million | $-6.76 Million | -0.245x | +19.02% |
| 2012-12-31 | $16.12 Million | $-4.88 Million | -0.303x | -90.52% |
| 2011-12-31 | $32.18 Million | $-5.11 Million | -0.159x | +51.43% |
| 2010-12-31 | $32.27 Million | $-10.55 Million | -0.327x | +37.45% |
| 2009-12-31 | $8.89 Million | $-4.65 Million | -0.523x | -0.67% |
| 2008-12-31 | $13.44 Million | $-6.98 Million | -0.519x | -139.48% |
| 2007-12-31 | $17.68 Million | $-3.83 Million | -0.217x | +15.48% |
| 2006-12-31 | $15.71 Million | $-4.03 Million | -0.257x | -44.68% |
| 2005-12-31 | $15.69 Million | $-2.78 Million | -0.177x | +83.24% |
| 2004-12-31 | $2.34 Million | $-2.48 Million | -1.058x | -169.58% |
| 2003-12-31 | $5.18 Million | $-2.04 Million | -0.393x | -59.14% |
| 2002-12-31 | $7.46 Million | $-1.84 Million | -0.247x | +3.33% |
| 2001-12-31 | $8.95 Million | $-2.28 Million | -0.255x | +0.60% |
| 2000-12-31 | $11.14 Million | $-2.86 Million | -0.257x | -108.48% |
| 1999-12-31 | $9.21 Million | $-1.13 Million | -0.123x | +77.21% |
| 1998-12-31 | $3.34 Million | $-1.81 Million | -0.540x | -64.85% |
| 1997-12-31 | $4.63 Million | $-1.52 Million | -0.328x | -188.07% |
| 1996-12-31 | $6.39 Million | $-727.00K | -0.114x | +58.72% |
| 1995-12-31 | $2.76 Million | $-761.00K | -0.276x | -- |
About Silence Therapeutics PLC
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated… Read more